Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Non-Current Assets (2023 - 2026)

Alto Neuroscience has reported Non-Current Assets over the past 4 years, most recently at $7.1 million for Q1 2026.

  • Quarterly results put Non-Current Assets at $7.1 million for Q1 2026, down 15.0% from a year ago — trailing twelve months through Mar 2026 was $29.7 million (up 11.52% YoY), and the annual figure for FY2025 was $7.0 million, down 15.04%.
  • Non-Current Assets reached $7.1 million in Q1 2026 per ANRO's latest filing, up from $7.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $8.4 million in Q1 2025 and bottomed at $1.2 million in Q4 2023.
  • Median Non-Current Assets over the past 4 years was $7.3 million (2025), compared with a mean of $5.9 million.
  • The largest annual shift saw Non-Current Assets surged 563.3% in 2024 before it dropped 15.04% in 2025.
  • Over 4 years, Non-Current Assets stood at $1.2 million in 2023, then soared by 563.3% to $8.2 million in 2024, then decreased by 15.04% to $7.0 million in 2025, then grew by 2.32% to $7.1 million in 2026.
  • Business Quant data shows Non-Current Assets for ANRO at $7.1 million in Q1 2026, $7.0 million in Q4 2025, and $7.6 million in Q3 2025.